A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Differentiation
- Vol. 70 (9-10) , 599-609
- https://doi.org/10.1046/j.1432-0436.2002.700913.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaNew England Journal of Medicine, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- STI571 (Gleevec™) as a paradigm for cancer therapyTrends in Molecular Medicine, 2002
- Perspectives on the development of a molecularly targeted agentCancer Cell, 2002
- Hypoxic cytotoxic agents: a new approach to cancer chemotherapyDrug Resistance Updates, 2000
- Requirement for p53 and p21 to Sustain G 2 Arrest After DNA DamageScience, 1998
- Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesisNature, 1998
- Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.British Journal of Cancer, 1998
- How Tumors Become AngiogenicAdvances in Cancer Research, 1996